AIチャット
Loading data for TSHA — first visit, this takes a few seconds.

Taysha Gene Therapies, Inc.

TSHA · NasdaqGS · USD

5.16 +0.09 (1.78%)

終値時点: Sep 16, 2026, 3:59 PM

5.10 +0.59%

寄り付き前: 7:50 AM

出来高
3.15M

Taysha Gene Therapies, Inc.(TSHA)の株価・分析・データ

本質的価値

本源的価値を読み込み中…

アナリスト予想

株価予想 →

アナリスト予測は利用できません

12か月目標株価 · アナリストn/a人

アナリストのコンセンサス: n/a

間隔:1D
ローソク足とシグナルを読み込み中…

業績

財務情報を見る →

読み込み中...

最新決算

実績予想との差前年比
売上高$0n/a-100.00%
EPS(TTM)-$0.13-$0.02-62.50%

次回決算

取引時間中の予定です。

予想 · アップグレード →

決算の詳細を見る →

事業指標

買気配
5.16
純利益(TTM)
-150M
1.17
-0.41
n/a
-10.96
PBR(TTM)
6.87
PSR(TTM)
301.18
決算発表日
Nov 4, 2026
売気配
6.51
出来高
3,148,132
平均出来高(20日)
3,211,585
始値
5.25
前日終値
5.07
当日レンジ
5.05 - 5.46
52週レンジ
2.71 - 7.30
配当
n/a
権利落ち日
n/a

Taysha Gene Therapies, Inc.について

企業情報を見る →
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. Biotechnology · Healthcare

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

セクター Healthcare
IPO日 Sep 24, 2020
従業員数 99
上場取引所 NasdaqGS
ティッカー TSHA
ウェブサイト https://www.tayshagtx.com